Pharmaceutical giant Pfizer has confirmed 160 jobs at one of its plants in Co Cork are safe for the foreseeable future due to a global upturn in demand for anti-cholesterol drug Lipitor.
The company’s Little Island plant had been earmarked for closure last August after an announcement, a year earlier, about job losses after Lipitor came off patent.
However, instead of a predicted crash, the opposite occurred and delighted staff were advised of job security for the foreseeable future.
The company said the decision had been mainly driven by volume increases for Lipitor, but there were also other factors including the commitment and continued excellence demonstrated by the workforce in the manufacturing fundamentals of safety, quality, supply and cost.
“The global manufacturing environment is very competitive and our colleagues have been key in helping drive the fundamentals that have enabled us to achieve greater competitiveness during the past few years,” said Seamus Fives, site leader for the Little Island and Ringaskiddy plants.
“The Little Island site has continued to demonstrate the highest levels of performance, flexibility and commitment to the work we are doing here and I am proud of what has been achieved.
“It is an example of how continuing to focus on competitiveness and adding business value generates business opportunities,” he said.
A global upturn in demand for Lipitor was noticeable, particularly in China and North America.
Pfizer was also manufacturing two new cancer drugs, Xalkori and Iniyta at the Little Island plant, but will shortly transfer production of those to Ringaskiddy.
© Irish Examiner Ltd. All rights reserved